•   
  •   
  •   

World Brazil Approves Import of China’s Sinovac Vaccine

03:00  24 october  2020
03:00  24 october  2020 Source:   bloomberg.com

Protecting the profits of a few could prevent vaccine access for all

  Protecting the profits of a few could prevent vaccine access for all India and South Africa have put forward a novel proposal to replace our current competition-driven approach with cooperation. At a meeting on Oct. 15, they will be asking the World Trade Organization (WTO) to temporarily relax its rules to allow for more international collaboration in the manufacture of the vaccines and medicines - even without authorization from the companies that created them. Theirs is an ambitious gambit, but one that deserves support. require(["medianetNativeAdOnArticle"], function (medianetNativeAdOnArticle) { medianetNativeAdOnArticle.

Brazilian President Jair Bolsonaro has said his government will not buy a Chinese -made Covid-19 vaccine , a day after his health minister said it would Responding to a supporter on social media who urged him not to buy the Sinovac vaccine , Mr Bolsonaro said: "We will not buy the Chinese vaccine ."

Sao Paulo (AFP) - Brazilian officials on Thursday announced an agreement with China ' s Sinovac Biotech to produce its coronavirus vaccine in the state of Sao Paulo, where tests involving 9,000 volunteers are to begin next month. Brazil has the world's second-highest coronavirus caseload after

(Bloomberg) -- Brazil’s health regulator authorized the import of a Chinese-produced vaccine after claims from President Jair Bolsonaro that the country lacked the creditability to develop a cure for the coronavirus.

BEIJING, CHINA - SEPTEMBER 24: Vials are seen on a tray in a lab at Sinovac Biotech where the company is producing their potential COVID-19 vaccine CoronaVac during a media tour on September 24, 2020 in Beijing, China. Sinovacs inactivated vaccine candidate, called CoronaVac, is among a number of companies in the global race to control the coronavirus pandemic. The company is running Phase 3 human trials in four countries and ramping up production to 300 million doses per year at a new manufacturing facility south of Beijing. A lack of domestic coronavirus cases in China has meant that companies developing vaccines have shifted their focus overseas to conduct trials to gather the volume of data necessary to win regulatory approvals. When Chinas government launched an emergency use program in July to vaccinate groups of essential workers, Sinovacs chief executive says the company supplied tens of thousands of doses, even as trials are still underway. About 90% of Sinovacs employees have chosen to receive injections of CoronaVac, which is one of eight Chinese vaccine candidates in human trials. The company is also seeking approval to begin clinical trials with teenagers and children as young as age 3.(Photo by Kevin Frayer/Getty Images) © Photographer: Kevin Frayer/Getty Images AsiaPac BEIJING, CHINA - SEPTEMBER 24: Vials are seen on a tray in a lab at Sinovac Biotech where the company is producing their potential COVID-19 vaccine CoronaVac during a media tour on September 24, 2020 in Beijing, China. Sinovacs inactivated vaccine candidate, called CoronaVac, is among a number of companies in the global race to control the coronavirus pandemic. The company is running Phase 3 human trials in four countries and ramping up production to 300 million doses per year at a new manufacturing facility south of Beijing. A lack of domestic coronavirus cases in China has meant that companies developing vaccines have shifted their focus overseas to conduct trials to gather the volume of data necessary to win regulatory approvals. When Chinas government launched an emergency use program in July to vaccinate groups of essential workers, Sinovacs chief executive says the company supplied tens of thousands of doses, even as trials are still underway. About 90% of Sinovacs employees have chosen to receive injections of CoronaVac, which is one of eight Chinese vaccine candidates in human trials. The company is also seeking approval to begin clinical trials with teenagers and children as young as age 3.(Photo by Kevin Frayer/Getty Images)

The Butantan Institute, a Sao Paulo research center that has partnered with Sinovac Biotech Ltd, was granted an “exceptional” permission to bring six million doses of the unregistered Coronavac drug into the country for phase three trials, the Brazilian Health Surveillance Agency, or Anvisa, said in a statement Friday afternoon.

Vaccine storage demands could leave 3B people in virus cold

  Vaccine storage demands could leave 3B people in virus cold GAMPELA, Burkina Faso (AP) — From factory to syringe, the world’s most promising coronavirus vaccine candidates need nonstop sterile refrigeration to work. But despite great strides in equipping developing countries to maintain the vaccine “cold chain,” nearly 3 billion of the world's 7.8 billion people live in places with insufficient temperature-controlled storage for an immunization campaign to bring COVID-19 under control. The result: PoorBut despite great strides in equipping developing countries to maintain the vaccine “cold chain,” nearly 3 billion of the world's 7.8 billion people live in places with insufficient temperature-controlled storage for an immunization campaign to bring COVID-19 under control.

An experimental coronavirus vaccine developed by China ' s Sinovac Biotech appeared to be safe in a late-stage clinical trial in Brazil , preliminary results showed on Monday. São Paulo's Butantan Institute, one of Brazil 's leading biomedical research centers, which is carrying out the Phase.

Brazilian Health Minister Eduardo Pazuello signed a letter of intent with the state of São Paulo to purchase 46 million doses of the CoronaVac vaccine , developed by China ’ s Sinovac Biotech. The vaccine is being developed in partnership with Instituto Butantan, located in São Paulo.

The trial has become the latest flash point in the fight between local leadership and Bolsonaro over the handling of the outbreak. The president said earlier this week that his government would not purchase the drug due “to its origin.”

Read more: Brazil’s Bolsonaro Escalates Feud Over China-Backed Vaccine

Sao Paulo Governor Joao Doria, a staunch Bolsonaro critic, said not proceeding with the Sinovac trial would be “criminal” and accused the president of politicizing the vaccine. Lower house speaker Rodrigo Maia presented a united front with Doria during a press conference Friday, calling him an “ally” and saying that he hoped that the president would reconsider his position.

The South American nation has faced one of the gravest pandemic tolls, registering nearly 156,000 deaths and over 5,333,000 cases.

For more articles like this, please visit us at bloomberg.com

©2020 Bloomberg L.P.

As the world awaits a coronavirus vaccine, some Chinese students get early doses .
One province began offering emergency vaccines to the public this month. But the 23-year-old is part of an extraordinary group: those who have received an early dose of a coronavirus vaccine, not in a clinical trial, but because they are Chinese citizens with overseas plans.

usr: 3
This is interesting!